Read by QxMD icon Read


shared collection
16 papers 0 to 25 followers Bioresorbable Everolimus-Eluting Vascular Scaffold o ABSORB
By Alessandro Iadanza Interventional Cardiologist at Siena University Hospital
Toru Naganuma, Antonio Colombo, Maciej Lesiak, Davide Capodanno, Tommaso Gori, Holger Nef, Giuseppe Caramanno, Christoph Naber, Carlo Di Mario, Neil Ruparelia, Piera Capranzano, Jens Wiebe, Aleksander Araszkiewicz, Salvatore Geraci, Hiroyoshi Kawamoto, Stelios Pyxaras, Alessio Mattesini, Thomas Münzel, Corrado Tamburino, Azeem Latib
OBJECTIVES: The aim of this study was to evaluate midterm outcomes of bioresorbable vascular scaffolds (BVS) implanted in bifurcation lesions. BACKGROUND: BVS have emerged as an alternative to conventional metallic drug-eluting stents for the treatment of coronary complex lesions. METHODS: Between November 2011 and January 2014, 1189 patients underwent percutaneous coronary intervention with BVS at 10 European centers (GHOST EU registry). Of these, 289 consecutive patients (302 bifurcation lesions) treated with either single-stenting (n = 260) or double-stenting (n = 42) were evaluated...
January 2017: Catheterization and Cardiovascular Interventions
Piera Capranzano, Luca Testa, Claudia Tamburino, Davide Capodanno, Giuseppe Biondi-Zoccai, Giovanni Longo, Fabrizio Tomai, Flavio Ribichini, Ciro Indolfi, Antonio L Bartorelli, Anna Sonia Petronio, Francesco Bedogni, Alessio La Manna, Bruno Francaviglia, Marco De Carlo, Corrado Tamburino
Currently, one of the most relevant innovations in interventional cardiology is the advent of bioresorbable vascular scaffolds (BVS). Among the BVS developed so far, the AbsorbTM BVS 1.1 (Abbott®) is one of the two devices that achieved the CE mark for the use in clinical practice. A reasonable amount of clinical evidence on AbsorbTM BVS has been built up from a large series of trials, of which some have been completed and others are in the enrollment and/or follow-up phases. However, at present there is paucity of data on the efficacy and safety of AbsorbTM BVS in patients with more complex coronary artery disease, who represent the majority of those undergoing coronary stenting in everyday clinical practice...
September 2014: Giornale Italiano di Cardiologia
James A Goldstein
No abstract text is available yet for this article.
November 2014: JACC. Cardiovascular Imaging
Davide Capodanno, Tommaso Gori, Holger Nef, Azeem Latib, Julinda Mehilli, Maciej Lesiak, Giuseppe Caramanno, Christoph Naber, Carlo Di Mario, Antonio Colombo, Piera Capranzano, Jens Wiebe, Aleksander Araszkiewicz, Salvatore Geraci, Stelios Pyxaras, Alessio Mattesini, Toru Naganuma, Thomas Münzel, Corrado Tamburino
AIMS: Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry. METHODS AND RESULTS: Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres...
February 2015: EuroIntervention
Alexandre Abizaid, J Ribamar Costa, Antonio L Bartorelli, Robert Whitbourn, Robert Jan van Geuns, Bernard Chevalier, Tejas Patel, Ashok Seth, Marrianne Stuteville, Cécile Dorange, Wai-Fung Cheong, Krishnankutty Sudhir, Patrick W Serruys
AIMS: The safety and performance of the Absorb Bioresorbable Vascular Scaffold (Absorb BVS) system (Abbott Vascular, Santa Clara, CA, USA) has been previously established in 131 patients from cohort A and cohort B of the first-in-man ABSORB trial. Following this trial, ABSORB EXTEND was initiated as a global continued access study (outside of the USA) to expand experience with the Absorb BVS system to different geographies with broader inclusion criteria to include the treatment of longer lesions and multiple vessels...
April 2015: EuroIntervention
Ashok Seth, G Sengottuvelu, V Ravisekar
Recent technological developments have led to the development of Absorb™ bioresorbable vascular scaffold (BVS) [Abbott Vascular, Santa Clara, USA] for percutaneous treatment of coronary artery disease by percutaneous coronary intervention (PCI). The BVS is now approved for use in many countries but experience in bifurcation lesions is limited and largely unreported and concerns still exist about its use across major side branches. We report for the first time, the successful use of the "T and Protrusion" (TAP) technique of deploying BVS into the side branch (SB) through the struts of main branch (MB) BVS to salvage a suboptimal result and threatened closure of a SB in three cases when treating bifurcation lesions with a planned single BVS strategy...
July 1, 2014: Catheterization and Cardiovascular Interventions
Lukasz Rzeszutko, Rafał Depukat, Dariusz Dudek
Since 2006, over 600 biodegradable vascular scaffolds (BVS) have been implanted worldwide in clinical trials such as ABSORB cohort A and B, ABSORB Extend and ABSORB II RCT. Due to completely changed construction and mechanical properties of BVS, the choice of proper scaffold diameter and its implantation differ significantly from those used in the case of metal stents (bare metal stent (BMS) or drug eluting stent (DES)). Furthermore, all data concerning BVS efficacy and safety come from clinical trials, conducted in a selected group of patients...
2013: Postępy W Kardiologii Interwencyjnej, Advances in Interventional Cardiology
Tommaso Gori, Giulio Guagliumi, Thomas Münzel
No abstract text is available yet for this article.
March 15, 2014: International Journal of Cardiology
Adam J Brown, Liam M McCormick, Denise M Braganza, Martin R Bennett, Stephen P Hoole, Nick E J West
OBJECTIVES: This study sought to investigate the postdeployment expansion and malapposition characteristics of the bioresorbable vascular scaffold (BVS) in real-world practice. BACKGROUND: The material construct of the BVS precludes overexpansion, with consequent potential for scaffold underexpansion and malapposition. In metallic stents, these features are associated with an increased risk of adverse events, including stent thrombosis. The postdeployment characteristics of the BVS are yet to be described outside clinical trials, where implantation occurred in straightforward lesion subsets...
July 1, 2014: Catheterization and Cardiovascular Interventions
Tommaso Gori, Eberhard Schulz, Ulrich Hink, Philip Wenzel, Felix Post, Alexander Jabs, Thomas Münzel
AIMS: The safety of BVS implantation in patients with a high risk for early thrombotic complications has not been studied. We report on the outcomes of patients with acute coronary syndromes (ACS) treated with bioresorbable, everolimus-eluting, vascular scaffolds (BVS). METHODS AND RESULTS: 150 consecutive patients with ACS (194 lesions) treated with BVS between May 2012 and July 2013 were compared with a control group composed of 103 consecutive patients (129 lesions) who underwent everolimus drug-eluting stent (DES) implantation in the same time period...
January 22, 2014: EuroIntervention
Sandeep Basavarajaiah, Toru Naganuma, Azeem Latib, Antonio Colombo
The technology of bioabsorbable vascular scaffolds (BVSs) that disappears with minimal trace essentially eliminating the risk of very late stent thrombosis appears exciting. However, these scaffolds have only been tried in simple lesions in which the risk of late stent thrombosis is very low. We would like to report the use of everolimus-eluting BVS in calcified coronary lesions following debulking the lesions using scoring balloons and rotational atherectomy. With the use of intravascular ultrasound, we have confirmed the adequate expansion of these scaffolds...
July 1, 2014: Catheterization and Cardiovascular Interventions
Roberto Diletti, Patrick W Serruys, Vasim Farooq, Krishnankutty Sudhir, Cecile Dorange, Karine Miquel-Hebert, Susan Veldhof, Richard Rapoza, Yoshinobu Onuma, Hector M Garcia-Garcia, Bernard Chevalier
BACKGROUND: Currently, no data are available on the direct comparison between the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) and conventional metallic drug-eluting stents. METHODS: The ABSORB II study is a randomized, active-controlled, single-blinded, multicenter clinical trial aiming to compare the second-generation Absorb BVS with the XIENCE everolimus-eluting metallic stent. Approximately 501 subjects will be enrolled on a 2:1 randomization basis (Absorb BVS/XIENCE stent) in approximately 40 investigational sites across Europe and New Zealand...
November 2012: American Heart Journal
Salvatore Brugaletta, Jung Ho Heo, Hector M Garcia-Garcia, Vasim Farooq, Robert Jan van Geuns, Bernard de Bruyne, Dariusz Dudek, Pieter C Smits, Jacques Koolen, Dougal McClean, Cecile Dorange, Susan Veldhof, Richard Rapoza, Yoshinobu Onuma, Nico Bruining, John A Ormiston, Patrick W Serruys
AIMS: To analyse the vasoreactivity of a coronary segment, previously scaffolded by the ABSORB bioresorbable vascular scaffold (BVS) device, in relationship to its intravascular ultrasound-virtual histology (IVUS-VH) composition and reduction in greyscale echogenicity of the struts. Coronary segments, transiently scaffolded by a polymeric device, may in the long-term recover a normal vasomotor tone. Recovery of a normal endothelial-dependent vasomotion may be enabled by scaffold bioresorption, composition of the underlying tissue, or a combination of both mechanisms...
June 2012: European Heart Journal
Patrick W Serruys, Yoshinobu Onuma, Dariusz Dudek, Pieter C Smits, Jacques Koolen, Bernard Chevalier, Bernard de Bruyne, Leif Thuesen, Dougal McClean, Robert-Jan van Geuns, Stephan Windecker, Robert Whitbourn, Ian Meredith, Cecile Dorange, Susan Veldhof, Karine Miquel Hebert, Krishnankutty Sudhir, Hector M Garcia-Garcia, John A Ormiston
OBJECTIVES: The aim of this study was to demonstrate that the prevention of early scaffold area shrinkage of the ABSORB BVS (Rev.1.1, Abbott Vascular, Santa Clara, California) was sustained and not simply delayed by a few months. BACKGROUND: With improved scaffold design and modified manufacturing process of its polymer, the second iteration of ABSORB (BVS 1.1) has improved performance to prevent a scaffold area reduction at 6 months. METHODS: Fifty-six patients were enrolled and received 57 ABSORB scaffolds...
October 4, 2011: Journal of the American College of Cardiology
Josep Gomez-Lara, Salvatore Brugaletta, Vasim Farooq, Robert Jan van Geuns, Bernard De Bruyne, Stephan Windecker, Dougal McClean, Leif Thuesen, Dariusz Dudek, Jacques Koolen, Robert Whitbourn, Pieter C Smits, Bernard Chevalier, Marie-Angèle Morel, Cécile Dorange, Susan Veldhof, Richard Rapoza, Hector M Garcia-Garcia, John A Ormiston, Patrick W Serruys
OBJECTIVES: The aim of this study was to compare the angiographic changes in coronary geometry of the bioresorbable vascular scaffolds (BVS) and metallic platform stent (MPS) between baseline and follow-up. BACKGROUND: Coronary geometry changes after stenting might result in wall shear stress changes and adverse events. The BVS have better conformability, compared with MPS, but still modify artery geometry. It is uncertain whether the BVS resorption can restore the coronary anatomical configuration at midterm follow-up...
July 2011: JACC. Cardiovascular Interventions
John A Ormiston, Patrick W Serruys, Evelyn Regar, Dariusz Dudek, Leif Thuesen, Mark W I Webster, Yoshinobu Onuma, Hector M Garcia-Garcia, Robert McGreevy, Susan Veldhof
BACKGROUND: A fully bioabsorbable drug-eluting coronary stent that scaffolds the vessel wall when needed and then disappears once the acute recoil and constrictive remodelling processes have subsided has theoretical advantages. The bioasorbable everolimus-eluting stent (BVS) has a backbone of poly-L-lactic acid that provides the support and a coating of poly-D,L-lactic acid that contains and controls the release of the antiproliferative agent everolimus. We assessed the feasibility and safety of this BVS stent...
March 15, 2008: Lancet
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"